Home
JournalsCollections
For Authors For Reviewers For Editorial Board Members
Article Processing Charges Open Access
Ethics Advertising Policy
Editorial Policy Resource Center
Company Information Contact Us Membership Collaborators Partners
Publications > Journals > Latest Articles
Results per page:
v
Original Article Open Access
Development, Implementation, and Clinical Outcomes of A Therapeutic Hypothermia Management Protocol for Patients with Neurocritical Illness: A Before-and-after Study
Yan Ouyang, Yanjun Luo, Yuxin Zhan, Min Liu, Qi Li, Wenjing Li, Lianlian Qu, Suyun Li
Published online September 28, 2026
Neurosurgical Subspecialties. doi:10.14218/NSSS.2026.00013
Abstract
Therapeutic hypothermia (TH) is widely used as a neuroprotective strategy, but variability in bedside implementation may limit its optimal application. This study aimed to develop [...] Read more.

Therapeutic hypothermia (TH) is widely used as a neuroprotective strategy, but variability in bedside implementation may limit its optimal application. This study aimed to develop a standardized TH management protocol for patients with neurocritical illness and evaluate the clinical outcomes associated with its implementation.

An evidence-based TH protocol was developed through a two-round Delphi consensus process. A subsequent observational before-and-after study included 244 patients with neurocritical illness receiving TH. The historical control group (n = 120) received routine care, whereas the TH protocol group (n = 124) was managed according to the standardized protocol. No single primary endpoint was prespecified for the final comparative analysis. Outcomes were interpreted as exploratory and included temperature-management process indicators, individual TH-related complications requiring intervention, and neurological outcomes assessed using the Glasgow Outcome Scale.

Protocol implementation was associated with more favorable temperature-management process indicators, including earlier TH initiation, a shorter recorded time to target temperature, fewer unplanned treatment interruptions, a longer controlled rewarming phase, and greater adherence to rewarming criteria. In exploratory analyses, the TH protocol group had lower incidences of selected TH-related complications and more favorable Glasgow Outcome Scale outcomes at discharge than the historical control group.

Implementation of a consensus-derived TH management protocol was associated with more consistent temperature-management processes, fewer selected TH-related complications, and more favorable short-term neurological outcomes. These findings support prospective evaluation of protocolized TH management in larger multicenter cohorts.

Full article
Review Article Open Access
Stratified Safety Evaluation Framework for Natural Products Based on New Approach Methodologies in Integrative Medicine: A Narrative Review
Manzhu Cao, Xiaoyan Duan, Jie Li, Ziqi Zhou, Hongtao Jin
Published online September 28, 2026
Future Integrative Medicine. doi:10.14218/FIM.2026.00017
Abstract
The widespread assumption that “natural” equals “safe” has been repeatedly challenged by adverse events associated with medicinal plant-derived products. Unlike synthetic pharmaceuticals, [...] Read more.

The widespread assumption that “natural” equals “safe” has been repeatedly challenged by adverse events associated with medicinal plant-derived products. Unlike synthetic pharmaceuticals, these natural products present distinct safety concerns because of their compositional complexity, inherent variability, and batch-to-batch inconsistency. Consequently, a one-size-fits-all approach to toxicological assessment is insufficient. In this narrative review, we propose a pragmatic “classify-then-evaluate” framework that stratifies natural products into three operational categories according to compositional complexity and degree of chemical characterization—TCM compound formulae, active fractions/extracts, and purified single compounds. This framework enables safety evaluations to be tailored to product complexity by integrating conventional toxicological assays with emerging new approach methodologies. By linking chemical characterization, hazard identification, quality control, and risk assessment within a tiered system, this framework bridges the gap between evidence generation and regulatory decision-making, offering a scientifically grounded and proportionate pathway for evaluating the safety of natural products used in integrative medicine, with a primary focus on herbal and TCM-related products. The review does not aim to provide a comprehensive systematic evidence map; further validation of the proposed framework is required

Full article
Guideline Open Access
Chinese Guideline for the Diagnosis and Treatment of Head, Thoracic, Abdominal, and Pelvic Polytrauma (2026 Edition)
Jian-Ning Zhang, Wang Jia, Yan-Bing Yu, Jia-Yu Liu, Zhi-Qiang Xue, Zhi Qiao, Xiang-Dang Liang, Xin Lou, Wei-Dong Mi, Tan-Shi Li, Fei-Hu Zhou, Gang Cheng, Jun-Zhao Sun, Wen-Ying Lv, De-Zhi Kang, Ning Wang, Rong-Cai Jiang, Jun-Ji Wei, Guo-Yi Gao, Zhou Fei, Hua Feng, Hai-Yan Zhu, Jiang-Bei Cao, Ke-Zhong Chen, Wei-Nan Liu, Zhi-Yong Liu, Yuan Gao, Hua Yan, Yong-Xin Wang, Jin-Fang Liu, Liang Wen, Neurosurgery Specialist Alliance of the Joint Logistics Support Force, Neurotrauma Society of the China, International Exchange, Promotive Association for Medical, Health Care, Neurotrauma Group of the Chinese Congress of Neurological Surgeons, and Craniocerebral Trauma Panel of the Neurosurgery Society of the Beijing Medical Association
Published online September 28, 2026
Neurosurgical Subspecialties. doi:10.14218/NSSS.2026.00016
Abstract
Head, thoracic, abdominal, and pelvic polytrauma is clinically complex and requires coordinated multidisciplinary care, creating an urgent need for standardized guidance. This guideline [...] Read more.

Head, thoracic, abdominal, and pelvic polytrauma is clinically complex and requires coordinated multidisciplinary care, creating an urgent need for standardized guidance. This guideline aims to provide an evidence-based foundation and clinical pathway for the diagnosis, assessment, damage control, surgical timing, and acute-phase management of patients with head, thoracic, abdominal, and pelvic polytrauma. Led by the Senior Department of Neurosurgery, Chinese PLA General Hospital, a multidisciplinary working group comprising experts in thoracic surgery, general surgery, orthopedics, critical care medicine, anesthesiology, radiology, emergency medicine, nursing, and related disciplines developed the guideline through systematic review of the relevant literature, consideration of the characteristics of trauma care in China’s military and civilian medical systems, and two rounds of expert voting and consensus decision-making. The guideline addresses 22 key clinical questions covering imaging assessment, damage-control resuscitation, prioritization of craniocerebral and torso injury management, anticoagulation and hemostatic management, intensive care, and early rehabilitation. A total of 22 recommendations were formulated by integrating evidence quality, clinical feasibility, and implementability, together with corresponding implementation points and quality-control indicators. The guideline emphasizes stabilization of vital signs, damage-control principles, multidisciplinary collaboration, standardized clinical pathways, and a tiered trauma-care system. Implementation of these recommendations may improve the consistency and timeliness of multidisciplinary care and provide a framework for reducing early mortality while preserving neurological and functional outcomes.

Full article
Original Article Open Access
Watertight-intent Versus Non-watertight Management in Decompressive Craniectomy: A Systematic Review and Meta-analysis
Zixuan Ma, Junfeng Feng
Published online September 28, 2026
Neurosurgical Subspecialties. doi:10.14218/NSSS.2026.00026
Abstract
Watertight-intent dural reconstruction may reduce incisional cerebrospinal fluid (CSF) leakage after decompressive craniectomy but may prolong surgery. We aimed to evaluate whether [...] Read more.

Watertight-intent dural reconstruction may reduce incisional cerebrospinal fluid (CSF) leakage after decompressive craniectomy but may prolong surgery. We aimed to evaluate whether watertight-intent reconstruction, compared with non-watertight management, was associated with direct postoperative incisional CSF leakage and operative time.

Five databases were searched through August 1, 2026. Comparative studies with explicit watertight or sealing-intent reconstruction and non-watertight comparators were included. The primary outcome was direct incisional CSF leakage; secondary outcomes included operative time, wound or surgical-site infection, hydrocephalus, mortality, and functional outcomes. Binary outcomes were expressed as risk ratios (RRs), and continuous outcomes as mean differences. Random-effects meta-analysis used restricted maximum likelihood estimation with Wald 95% confidence intervals (CIs); randomized and observational studies were examined as subgroups, with Hartung–Knapp sensitivity analyses. Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation framework.

Twelve studies were included; nine (1,314 participants) reported direct incisional CSF leakage. Watertight-intent reconstruction was associated with fewer reported leaks (RR, 0.54; Wald 95% CI, 0.34–0.86; I² = 23.3%), although the prediction interval included the null value (0.24–1.20). The randomized subgroup was imprecise (RR, 0.75; 95% CI, 0.32–1.73), whereas the observational subgroup favored reconstruction (RR, 0.43; 95% CI, 0.20–0.90); its Hartung–Knapp interval (0.14–1.32) crossed 1. Infection and hydrocephalus estimates were imprecise; mortality and function were not pooled. Reconstruction was associated with longer operative time (mean difference, 39.85 minutes; 95% CI, 25.14–54.56; I² = 97.4%). Certainty was very low for all key outcomes.

Watertight-intent reconstruction is associated with fewer reported incisional CSF leaks and longer operations, although certainty is very low. Limited study and event numbers, imprecise design subgroups, and multicomponent techniques preclude causal or universal treatment conclusions. Effects on infection, hydrocephalus, mortality, and function remain uncertain.

Full article
Guideline Open Access
Evidence-based Guidelines for Standardized Pathologic Sampling and Diagnostic Reporting of Pancreatic Cancer in China
Hui Jiang, Yelin Yang, Yunshuo Zhang, Jianming Zheng
Published online September 28, 2026
Cancer Screening and Prevention. doi:10.14218/CSP.2026.00001
Abstract
Standardized pathologic sampling and reporting are essential for pancreatic cancer staging, prognosis assessment, and comparable clinical data. This guideline aimed to develop evidence-based [...] Read more.

Standardized pathologic sampling and reporting are essential for pancreatic cancer staging, prognosis assessment, and comparable clinical data. This guideline aimed to develop evidence-based recommendations for standardized pathologic sampling and diagnostic reporting of pancreatic cancer in China. Literature searches were conducted in English and Chinese databases, guideline websites, Google, and reference lists for records published before December 31, 2023. Two investigators screened and extracted the evidence; methodological quality and certainty were assessed using AMSTAR/AGREE II and GRADE, respectively; and recommendations were formulated through two rounds of modified Delphi consultations, with an agreement threshold of ≥ 75% for consensus. The final guideline includes 11 recommendations, including six strong and five weak recommendations, addressing margin and surface assessment, sampling methods, histologic classification and grading, lymphovascular and perineural invasion, TNM staging, tumor regression grading after neoadjuvant therapy, background lesions, and structured reporting. These recommendations provide a standardized framework for pathologic assessment and reporting of pancreatic cancer resection specimens and may support more consistent prognostic evaluation and clinical decision-making.

Full article
Opinion Open Access
Review Article Open Access
Evaluation of Human Serum Albumin in Neurocritical Care: A Narrative Review of Current Applications and Treatment Challenges
Songgen Jin, Yunpeng Luo, Songliu Yang, Shixing Wu, Changsong Wang
Published online September 28, 2026
Journal of Translational Critical Care Medicine. doi:10.14218/JTCCM.2026.00003S
Abstract
Human serum albumin (HSA) is a multifunctional carrier protein that helps maintain vascular barrier integrity and intravascular fluid homeostasis and has long been used in the management [...] Read more.

Human serum albumin (HSA) is a multifunctional carrier protein that helps maintain vascular barrier integrity and intravascular fluid homeostasis and has long been used in the management of critically ill patients, including those with acute brain injury. HSA is thought to exert neuroprotective effects through four complementary mechanisms: oncotic/volume expansion and hemodilution, antioxidant and anti-inflammatory effects, HSA-nitric oxide-mediated antithrombotic activity, and glycocalyx stabilization, although the precise pathways remain incompletely understood. Despite its biological rationale, the clinical efficacy of HSA in severe neurological disorders remains inconclusive, and few guidelines provide specific recommendations for its use in neurological care. This uncertainty stems primarily from the complex etiology and heterogeneous pathophysiology of neurological disorders, as well as inconsistent findings across existing studies. This narrative review aims to summarize the current evidence on HSA use in traumatic brain injury, acute ischemic stroke, and aneurysmal subarachnoid hemorrhage, identify existing knowledge gaps, and provide insights for future research and clinical practice. We screened records from PubMed, Embase, the Cochrane Library, CNKI, and Yiigle, as well as ClinicalTrials.gov, ChiCTR, and ChinaDrugTrials. A total of 29 human and animal studies were included. Collectively, available evidence supports a biological rationale for HSA therapy in neurocritical care, yet its clinical benefit remains incompletely established and substantial challenges persist. Prospective randomized controlled trials are warranted to clarify the efficacy and safety of HSA and determine whether preliminary encouraging findings can inform standardized guidelines and expert consensus recommendations, particularly regarding optimal concentration, timing, and patient selection.

Full article
Original Article Open Access
CXCR2 and SSTR2 Expression in Pancreatic and Small Intestinal Neuroendocrine Tumors: A Cross-Sectional Study
Xiangshan Fan, Kristen Logan, Huihua Li, Wei Chen, Jiaoti Huang, Michael A. Morse, Chanjuan Shi
Published online September 24, 2026
Journal of Clinical and Translational Pathology. doi:10.14218/JCTP.2026.00013
Abstract
CXC chemokine receptor 2 (CXCR2) expression has been observed in normal neuroendocrine cells, but its role in neuroendocrine neoplasms is less well established. We aimed to evaluate [...] Read more.

CXC chemokine receptor 2 (CXCR2) expression has been observed in normal neuroendocrine cells, but its role in neuroendocrine neoplasms is less well established. We aimed to evaluate CXCR2 expression with somatostatin receptor type 2 (SSTR2) expression in pancreatic neuroendocrine tumors (PanNETs) and small intestinal neuroendocrine tumors (SI-NETs).

This was a cross-sectional study. Pathology archives were searched for PanNETs with ≥2 resected liver metastases and SI-NETs with resected liver metastases, mesenteric tumor deposits (MTDs), and/or peritoneal metastases. Immunohistochemistry for CXCR2 was performed on de-identified tissue microarrays containing PanNETs and SI-NETs. SSTR2 and CXCR2 immunohistochemistry was also performed on tumor blocks from primary and metastatic PanNETs and SI-NETs. Based on H-scores, expression was scored as negative (<50), weak (50–100), moderate (>100–200), or strong (>200). Marker expression was descriptively reported among primary tumors, liver metastases, MTDs, and peritoneal metastases.

Among 12 primary PanNETs and 38 liver metastases, mean CXCR2 H-scores were 269.6 ± 36.7 and 254.6 ± 75.5, respectively, and mean SSTR2 H-scores were 261.5 ± 61.9 and 259.3 ± 70.9, respectively. All 84 SI-NET lesions showed moderate/strong CXCR2 expression, whereas 12 showed negative/weak SSTR2 expression. CXCR2 H-scores were 284.0 ± 26.5 in primary tumors, 272.5 ± 28.7 in MTDs, 269.6 ± 42.8 in liver metastases, and 265.0 ± 51.5 in peritoneal metastases. SSTR2 expression appears to be lower in MTDs than in primary tumors (182.2 ± 76.5 vs 235.9 ± 55.9).

CXCR2 is moderately/strongly expressed in most sampled PanNETs and all sampled SI-NETs. In SI-NETs, moderate/strong CXCR2 expression is less heterogeneous than SSTR2 expression.

Full article
Original Article Open Access
Comparison of Survival Between Patients with Hepatocellular Carcinoma Beyond the “Up-to-7” Criterion Who Received Adjuvant PD-1 Inhibitors or Active Surveillance: A Target Trial Emulation Study
Jia-Yong Su, Zhen Liu, Tai-Xin Yang, Ping-Ping Guo, Min Luo, Shao-Ping Liu, Xiao-Feng Dong, Xiao-Ling Xu, Shu-Chang Chen, Jun-Jie Ou, Kang Chen, Zhi-Cheng Li, Ze Su, Fu-Quan Yang, Wen-Hai He, Ning Peng, Pei-Sheng Wu, Bei-Bei Long, Hang Su, Mei-Lan Huang, Wen-Ting Li, Wen-Ting Chen, Jian-Rong Li, Da-Long Yang, Zhi-Hao Huang, Lei-Po Lin, Rong-Rui Huo, Yi-Li Ma, Liang Ma, Xiao-Bin Zhong, Jian-Hong Zhong, on behalf of the GUIDANCE investigators
Published online September 24, 2026
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00283
Abstract
The IMbrave050 trial suggested that adjuvant immune checkpoint inhibitor therapy may benefit patients with hepatocellular carcinoma exceeding the “up-to-7” criterion. This study [...] Read more.

The IMbrave050 trial suggested that adjuvant immune checkpoint inhibitor therapy may benefit patients with hepatocellular carcinoma exceeding the “up-to-7” criterion. This study aimed to compare survival outcomes and safety between such patients receiving adjuvant programmed cell death protein 1 inhibitors and those undergoing active surveillance after curative resection.

Data were prospectively collected from patients at 13 medical centers in China between 2019 and 2024. The study was designed according to a target trial emulation framework, and propensity score matching was used to reduce confounding. The primary endpoint was recurrence-free survival; secondary endpoints included overall survival and incidence of treatment-related adverse events.

Median follow-up was 32.7 months (interquartile range, 20.9–47.5). Propensity score matching yielded 200 patients per group. Median recurrence-free survival was longer in the adjuvant group (28.0 months; 95% confidence interval [CI], 21.7–34.3) than in the surveillance group (14.4 months; 95% CI, 10.7–18.1; hazard ratio, 0.58; 95% CI, 0.45–0.74). Median overall survival was not reached in the adjuvant group and was 45.0 months (95% CI, 37.8–52.1) in the surveillance group (hazard ratio, 0.63; 95% CI, 0.45–0.89). The most frequent grade 3–4 treatment-related adverse events were hand–foot skin reaction (7.2%), elevated alanine aminotransferase (5.8%), and elevated aspartate aminotransferase (5.3%).

Adjuvant programmed cell death protein 1 inhibitors, with or without molecularly targeted agents, were associated with longer recurrence-free survival and acceptable safety in patients with hepatocellular carcinoma exceeding the “up-to-7” criterion.

Full article
Review Article Open Access
DNA Methylation Biomarkers: From Precancerous Lesions to Adenocarcinoma in the Stomach and Esophagus
Maylynn Hu, Zhongren Zhou
Published online September 24, 2026
Journal of Clinical and Translational Pathology. doi:10.14218/JCTP.2026.00024
Abstract
Esophageal adenocarcinoma (EAC) and gastric cancer (GC) remain major causes of cancer-related mortality worldwide, largely because of late-stage diagnosis. Barrett’s esophagus (BE) [...] Read more.

Esophageal adenocarcinoma (EAC) and gastric cancer (GC) remain major causes of cancer-related mortality worldwide, largely because of late-stage diagnosis. Barrett’s esophagus (BE) is the established precursor setting for EAC, whereas gastric intestinal metaplasia is an important precursor lesion in the intestinal-type gastric carcinogenesis pathway. Aberrant DNA methylation arises early in both pathways and may offer greater sensitivity and specificity than histology or serology alone, while also illuminating the biology of neoplastic progression. This review evaluates the evidence and translational potential of DNA methylation biomarkers in upper gastrointestinal adenocarcinoma.

PubMed, Web of Science, and EMBASE were searched for studies published before May 2026 addressing DNA methylation biomarkers in BE, EAC, gastric intestinal metaplasia, and GC. Tissue-based, minimally invasive, and circulating biomarkers were reviewed, with emphasis on diagnostic performance, progression risk, biological significance, and clinical translation.

Methylation alterations accumulate during progression from precancerous lesions to invasive cancer and distinguish disease states in tissue and minimally invasive specimens. Methylation-based assays show promising diagnostic performance in BE and EAC, including nonendoscopic cytology-based approaches and risk-stratification assays, and circulating methylated DNA shows potential for noninvasive detection of EAC and GC. However, heterogeneity in populations, specimens, assay platforms, and study designs, together with limited prospective validation, remains a barrier to implementation.

The field is moving rapidly from discovery toward practice: Cytosponge-TFF3 with biomarker panels has been evaluated in real-world UK surveillance pathways, the EsoCheck/EsoGuard methylation assay is clinically available, and Esopredict is the first epigenetic prognostic assay clinically validated to risk-stratify BE, while multicancer early detection assays undergo prospective evaluation. Multicenter studies of clinical utility and cost-effectiveness remain the decisive step before routine adoption.

Full article
PrevPage 6 of 10 12…567…910Next